Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

http://www.wikidata.org/entity/Q37338486

about

Genetics and biology of pancreatic ductal adenocarcinoma The bromodomain: from epigenome reader to druggable target Targeting BET bromodomains for cancer treatment Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc Molecular pathways and therapeutic targets in lung cancer Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma Therapeutic strategies to inhibit MYC Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.Induced protein degradation: an emerging drug discovery paradigm.Identification of small molecule modulators of gene transcription with anticancer activity.Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.BRD4 inhibitor inhibits colorectal cancer growth and metastasis.BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.Strategies to Inhibit Myc and Their Clinical Applicability RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System Targeting BET bromodomain proteins in solid tumors JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Bromodomains and their pharmacological inhibitors.Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery.Non-small-cell lung cancers: a heterogeneous set of diseases.The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.Lineage factors and differentiation states in lung cancer progression.MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway.Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.

P2860

Q26765438-5C026E7F-B451-4A49-879F-24AB00DE375B Q26999935-8D80CF40-CEE2-4576-BB5D-E10B3B4564EB Q28263519-D5F6001E-ED19-437E-BA26-0D7852C0AA6C Q28647939-556D15CC-9BF4-4BEC-9003-2C40F7262508 Q33688872-DBFD6B08-DB21-4F46-8C0A-68EF395BEBB3 Q33761645-554BCFD5-D43D-481D-9AB1-4942EA66B08A Q34355349-CC76DFD2-FD8E-4FF2-B841-A5A34883E568 Q34479551-71A829E8-0DEA-46F8-AEE9-65EA2611E909 Q34489749-6C3F5CF5-840D-46D0-908C-557744C78E5E Q34545841-431965E5-A129-4F05-AD5F-993B8082FEBE Q34576203-AEAA4E3B-14F6-43A0-AFC6-08C33B358B1A Q34860750-FC46E9CE-F7B6-442D-B7EC-25D5C531FACB Q35016695-DD8DF0EC-2787-4D59-9641-345F90DC43FF Q35066871-680D6EA4-D92F-4913-A509-7E928EA7C0A2 Q35580851-93343911-B678-495C-B3BA-71AC839AFADA Q36303678-582E3E94-08A5-4A8A-82D8-1DFC1A411114 Q36398735-F98CC45E-B6BD-4B6E-9DC8-9453676270B7 Q36420155-9B23F90E-794E-4CA4-81CA-45FDFCE1623F Q36545758-3D347325-EB21-426D-AAB2-96F7375E4CE9 Q36560365-B373F495-FD3A-464F-B68C-6D7D634DB91A Q36693297-45A7B066-13D2-4405-935B-0CEF0C963A3B Q37123636-379DEDCA-6023-491E-951B-A060917F4C74 Q37161750-5CDA56F5-DDA8-46D3-B525-125FBF970219 Q37269236-0995CC5F-9D21-4D4A-B346-8FF43DFDC212 Q37330876-CB510C33-AB14-4212-9718-60A1A3397309 Q37611723-CFBDB690-C16A-48CE-B88B-598BA25946C6 Q37619860-CF2257B1-C6C6-4245-BC4E-580057532417 Q37687075-069A3951-2684-4AB3-931D-F913AD26AC28 Q37691709-CFCE90CE-41D6-4B53-A009-DB63CEED1648 Q37705651-802394DC-30D8-4E18-BAB7-2C12D98A6274 Q38185355-3329758D-4C37-401F-9919-41CD90010C55 Q38213677-280AFF8D-4E04-48D2-8264-71DD08700392 Q38233321-65AE2290-6BF7-4D70-9DC7-E5E9E49B6743 Q38260084-1C9D383E-E2A7-435D-953B-DF62A59DCC19 Q38395972-1BE3DCD5-0EDB-4F05-A888-00063F18789B Q38539670-7B647220-63CA-424D-8C86-EFB70B324A4A Q38547122-FB44939B-5107-490E-A73C-6702E0FC037E Q38582589-2E9EA535-A512-4824-970A-6CD631FB5702 Q38647306-61685524-6D34-43DA-B03B-CA900867EED6 Q38689201-C8255DD0-AC25-454F-A574-9A6976DC56EE

P2860

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

http://www.wikidata.org/entity/Q37338486

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@en

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@nl

type

label

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@en

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@nl

prefLabel

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@en

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@nl

P1433

Q37338486-327B6723-3785-41A8-8D87-C0B685BAAE3A

P1476

Q37338486-39A26710-946E-4D8D-80FA-C693AA794ACD

P2093

Q37338486-0D237E6A-769B-4ED7-A88F-1E785D16A6AA

Q37338486-18B0C5E1-29D7-483E-AB79-55CB6838CEDA

Q37338486-2221E4E2-B0B1-4FED-A251-64B64B102B9A

Q37338486-32D6998A-6DE9-4243-AB45-6863390FF9FA

Q37338486-877312E7-8B63-4C4D-BEE4-4F84A9DF158C

Q37338486-95F33E2F-A737-49D8-8C70-A1978B6AA0ED

Q37338486-AF620990-B7DA-4BFE-B60B-B679D28E4D8D

Q37338486-DC91166A-AE32-4E12-8779-CA54A1F13391

Q37338486-F6B15895-D856-4838-85BA-4EB238547AAA

Q37338486-FD6BD25D-D51F-43C1-9CDE-A099CA61C40D

P2860

Q37338486-0072B336-0C08-4AD7-B02B-651414F0A321

Q37338486-0A85BC20-4EA4-4B14-BEF5-B558C4070E22

Q37338486-14712FE4-BAE0-4DA2-93F8-D86B1F45B8D1

Q37338486-27B8B877-8483-4582-A3DE-1BDFDC3D7CB7

Q37338486-31BD1BF3-3BA5-4DBF-8708-E5A5229467E9

Q37338486-33451883-8225-46C0-AEE9-65F9732F4AFC

Q37338486-36502565-E1CE-4AC8-B709-8FFD27827F5A

Q37338486-3DFC01A7-8A84-4B14-BF22-3F332720769E

Q37338486-4BCC55FF-12F5-4173-B27B-ED454E7428DE

Q37338486-55A3C983-4FF3-4105-A110-670B03DFB322

P304

Q37338486-FF458B0C-FD43-48D8-96D6-03AD03051DAE

P31

Q37338486-73BD6F4E-36E1-47E1-A9EB-AAF71EE4AEB0

P356

Q37338486-4DDE4425-9718-4242-80AF-9306DA39D285

P407

Q37338486-A758E9A3-046D-4A12-8B15-D8A5FE0C7600

P433

Q37338486-59DCC917-A609-4B80-BBC6-73E5B9469BF6

P478

Q37338486-F979A9CE-67BB-4610-A71D-5DF135247CFC

P50

Q37338486-29CCFA95-5FB2-4279-B834-DE0268EBB982

Q37338486-2B9571CE-A456-47F7-A877-A88D4808770B

Q37338486-2EDC6635-4F75-4D66-B49B-98D1DB61D777

Q37338486-6E45AF45-A038-4D69-A8B1-8C624AE5F3A9

P577

Q37338486-347A4B5D-B628-48EE-AE90-05D34373F2B4

P698

Q37338486-C7B4DEA2-6192-4896-985B-445CA70106A4

P932

Q37338486-D11A6A9E-9093-4105-9037-DA4C2EFEC2EC

P356

1078-0432.CCR-12-3904

P1433

Clinical Cancer Research

P1476

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@en

P2093

Alec C Kimmelman

http://www.w3.org/2001/XMLSchema#string

Eiki Kikuchi

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jeremy H Tchaicha

http://www.w3.org/2001/XMLSchema#string

Jun Qi

http://www.w3.org/2001/XMLSchema#string

Katherine A Cheng

http://www.w3.org/2001/XMLSchema#string

Margaret Soucheray

http://www.w3.org/2001/XMLSchema#string

Takeshi Shimamura

http://www.w3.org/2001/XMLSchema#string

Travis J Cohoon

http://www.w3.org/2001/XMLSchema#string

Yandi Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

c-MYC: more than just a matter of life and death

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

RAS oncogenes: weaving a tumorigenic web

The landscape of somatic copy-number alteration across human cancers.

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

P304

6183-6192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-3904

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Julian Carretero

P577

2013-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24045185

http://www.w3.org/2001/XMLSchema#string

P932

3838895

http://www.w3.org/2001/XMLSchema#string